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ABSTRACT
Objectives: To compare the clinical and radiological
efficacy of initial vs delayed treatment with methotrexate
(MTX) and infliximab (IFX) in patients with recent onset
rheumatoid arthritis (RA).
Methods: In a post hoc analysis of the BeSt study (for
Behandel Stratagieen, Dutch for treatment strategies),
117 patients who started initial MTX+IFX were compared
with 67 patients who started MTX+IFX treatment after
failing (disease activity score (DAS).2.4; median delay to
IFX: 13 months) on >3 traditional DMARDs. If the DAS
remained .2.4, the protocol dictated IFX dose increases
to 6, 7.5 and 10 mg/kg. In case of a DAS (2.4 for
>6 months, IFX was tapered and finally stopped. We
aimed to correct for allocation bias using propensity
scores. Functional ability was measured by the Health
Assessment Questionnaire (HAQ), radiological progression
by Sharp/van der Heijde scoring (SHS).
Results: Baseline differences between the initial and
delayed groups were no longer significant after propensity
score adjustment. At 3 years after baseline, patients
treated with initial MTX+IFX experienced more improve-
ment in HAQ over time and were less likely to have SHS
progression than patients treated with delayed MTX+IFX
(p = 0.034). At 2 years after IFX initiation, more patients
in the initial group compared with the delayed group could
discontinue IFX after a good response (56% vs 29%,
p = 0.008).
Conclusions: The results of this post hoc analysis
suggest that using MTX+IFX as initial treatment for
patients with recent onset RA is more effective than
reserving MTX+IFX for patients who failed on traditional
DMARDs, with more HAQ improvement over time, more
IFX discontinuation and less progression of joint damage.
In the past few decades, the treatment outcomes of
patients with rheumatoid arthritis (RA) have
improved dramatically. Several studies have clearly
shown that immediate introduction of disease-
modifying antirheumatic drugs (DMARDs) after
diagnosis is superior to delayed introduction,1–3 which
led to the hypothesis that a window of opportunity
exists in which the disease process can be altered.4 5
The tumour necrosis factor (TNF) antagonists
infliximab (IFX), adalimumab and etanercept each
have proven to reduce disease activity and suppress
radiographic joint damage more adequately than
methotrexate (MTX) alone in patients with recent
onset6–8 and established RA.9–11 However, the costs
of TNF antagonists are considerable and there is
ongoing debate on their safety.12–14 Additionally, in
approximately a third of patients MTX mono-
therapy will provide sufficient improvement.15 16
Currently, in The Netherlands and in many other
countries TNF antagonists are reimbursed only for
patients who have failed to respond to at least two
traditional DMARDs.
It may be questioned whether ‘‘delayed anti-TNF
treatment’’ after failure on traditional DMARDs is
the most effective way of employing these potent
drugs. Quinn and colleagues demonstrated that with
initial MTX+IFX therapy, remission was achieved in
9 out of 10 patients after 1 year and sustained in 7
out of 9 patients after discontinuation of IFX.17 In
the BeSt study (for Behandel stratagieen, Dutch for
treatment strategies), 56% of patients with early RA
who were treated with initial MTX+IFX therapy
discontinued IFX within the first year and main-
tained a good response throughout the second year.18
Although it is conceivable that initial treatment
with TNF antagonists is superior to delayed treat-
ment, reports directly comparing initial vs delayed
institution of TNF antagonists are scarce.19 20
The current analysis is a post hoc analysis of the
BeSt study21 22 and aims to compare initial treat-
ment with MTX+IFX in group 4 with delayed
treatment with MTX+IFX after failure on previous
DMARDs in groups 1, 2 and 3. Because it is likely
that patients who proceed to delayed MTX+IFX
represent a selection of patients with more severe
RA, we aimed to correct for allocation bias using
propensity scores.23 24
METHODS
This is a post hoc analysis from the BeSt study; a
randomised controlled trial comparing four differ-
ent treatment strategies in patients with active,
recent onset RA. The detailed inclusion criteria
have been described previously.21 The medical
ethics committees of all participating centres
approved the study protocol and all patients gave
written informed consent before inclusion.
Treatment strategies were sequential monother-
apy (group 1, n = 126), step-up combination
therapy (group 2, n = 121), initial combination
therapy including prednisone (group 3, n = 133)
and initial combination therapy with MTX+IFX
(group 4, n = 128). Every 3 months, the disease
activity score (DAS, 44 joint count)25 was calcu-
lated. In case of a DAS of .2.4 or intolerable side
effects, treatment was adjusted to the next step in
the protocol.
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Patients randomised to groups 1, 2 and 3 started treatment
with ‘‘delayed MTX+IFX’’ after at least three traditional
DMARDs were tried and failed: in group 1, MTX monotherapy
25 mg/week, then sulfasalazine (SSA) monotherapy 2000–
3000 mg/day, then leflunomide monotherapy 20 mg/day; in
group 2, MTX monotherapy 25 mg/week, then MTX+SSA
2000–3000 mg/day, then MTX+SSA+hydroxychloroquine
(HCQ) 400 mg/day, then MTX+SSA+HCQ+prednisone
7.5 mg/day; and in group 3, MTX+SSA+prednisone 60 mg/
day, tapered to 7.5 mg/day in 7 weeks, then MTX+ciclosporine
2.5 mg/kg/day plus prednisone 7.5 mg/day. MTX was always
combined with folic acid 1 mg/day.
In all groups, treatment with MTX+IFX consisted of MTX
25 mg/week and IFX 3 mg/kg (at t = 0, 2 and 6 weeks, then
every 8 weeks). If the DAS was .2.4 a week before the next
infusion, the next dose of IFX was increased (to 6 mg/kg,
7.5 mg/kg and finally 10 mg/kg). If the DAS was (2.4 for at
least 6 months consecutively, IFX was tapered and finally
discontinued.
Patients who started initial MTX+IFX in group 4, as well as
patients who started delayed MTX+IFX in the other groups,
within 2 years from enrolment in the BeSt study, were
included. All patients were followed prospectively for 3 years
from the moment of inclusion in the BeSt study.
Study endpoints
The primary endpoints were functional ability, measured by the
Health Assessment Questionnaire (HAQ),26 and progression of
radiographic joint damage, scored on anonymised radiographs of
the hands and feet at baseline and after 3-years follow-up
according to the van der Heijde modified Sharp Score (SHS),27 in
random order, by two independent readers. The interobserver
intraclass correlation coefficient was 0.96. Progression of joint
damage was defined as a change in total SHS greater than the
smallest detectable change (SDC),28 which was 4.3 units.
Secondary outcomes were the discontinuation of IFX due to a
good response (measured in all patients who started IFX, in a
2-year period from the moment MTX+IFX was started), the
cumulative IFX doses received and treatment related serious
adverse events.
Statistical analysis
Baseline characteristics were compared using the x2 test, the
Student t test or the Mann–Whitney U test depending on the
tested variable. Since patients in the delayed MTX+IFX group
were likely to represent a selection of patients with more severe
RA, we aimed to adjust for allocation bias using propensity
scoring.23 We selected 30 baseline demographic and disease
characteristics in total and put these into a logistic regression
model to predict the probability of patients in groups 1 to 3
proceeding to delayed MTX+IFX. This model was then used to
calculate the predicted probability (propensity) of delayed
MTX+IFX treatment for each patient in groups 1 through 4.
Next, patients who actually received MTX+IFX were divided
into five quintiles based on the probability of receiving delayed
MTX+IFX. Within each quintile, baseline variables are expected
to be balanced between the initial and delayed group, in which
case any within-quintile difference in outcome is assumed to be
due to the difference in treatment. Variables within the
quintiles were compared between the two groups using the
Figure 1 Flowchart of the study. Reasons for dropout were: deceased due to disseminated tuberculosis (n = 1), deceased due to myocardial
infarction (n = 1) and patient refusal (n = 1). IFX, infliximab; MTX, methotrexate.
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Mantel–Haenzel test. The fit of the model was assessed by the
Hosmer–Lemeshow test; the discriminatory ability was assessed
by calculating the area under a receiver operating characteristic
(ROC) curve. We performed longitudinal data analysis of the
HAQ using a repeated measures analysis, with treatment, time
and their interaction as fixed effects. Means adjusted for
propensity quintile were estimated by these models. Logistic
regression was used to analyse radiographic progression .SDC
and IFX discontinuation adjusted for propensity quintile. In
view of the possibility of selection bias as a result of treatment
dynamics, we also investigated the primary endpoints of the
delayed group separately for groups 1, 2 and 3. The cumulative
IFX doses (mg/kg during 3-year follow-up) were calculated and
compared between both groups using the Student t test.
RESULTS
Complete baseline data for calculating propensity scores were
available in 117 patients (98%) treated with initial MTX+IFX
and 67 patients (97%) treated with delayed MTX+IFX (fig 1).
Three patients did not complete 3-years follow-up. Patients in
the delayed MTX+IFX group tended to be more often females of
younger age, with more active disease at inclusion (table 1).
The median (IQR) delay of MTX+IFX therapy in the delayed
group was 13 (12–17) months. At the time of MTX+IFX
initiation, functioning in the delayed group had already
improved (average delta HAQ of 20.38) due to on average
13 months of traditional DMARD therapy. Within the delayed
group, patients from groups 1, 2 and 3 had comparable
demographic and disease characteristics at baseline, except for
a lower median SHS in group 3 compared with groups 1 and 2
(1.5 vs 4.5 and 5.5, respectively; p,0.05).
Propensity model
The propensity model had an overall accuracy of 83% and
included the following 30 baseline covariates: gender; age at
inclusion; symptom duration; disease duration; height; weight;
body mass index (BMI); alcohol consumption; smoking;
rheumatoid factor (RF) status; anti-cyclic citrullinated peptide
(anti-CCP) status; previous antimalarial therapy; hormonal
replacement therapy; DAS; DAS in 3 categories ((3.8, 3.8–5.1
and .5.1); ESR; Ritchie articular index; swollen joint count;
patient’s assessments of global health, pain, disease activity,
morning stiffness and doctor’s assessment of disease activity on
a 0–100 mm VAS; HAQ; erosive disease; erosion score;
narrowing score; total SHS; as well as interaction terms for
smoking and RF status and for gender and menopausal status.
The model fit by the Hosmer–Lemeshow test was good
(p = 0.85). The area under the ROC curve (95% CI) was 0.77
(0.71 to 0.83), indicating good discrimination. The 184 patients
were divided into 5 quintiles based on the propensity score,
derived from the logistic regression analysis. Table 2 shows the
distribution of the baseline variables in five propensity quintiles.
As expected, patients with the highest propensity to proceed to
delayed MTX+IFX had more active disease, higher HAQ scores,
were more often female and RF positive and were of younger
age. Within the five propensity quintiles, baseline demographic
and disease characteristics were comparable between the initial
and delayed groups (p.0.05, by Mantel–Haenzel test).
Functional ability
Patients in the initial group showed more improvement in
functioning from baseline than patients in the delayed group, as
observed by longitudinal data analysis adjusted for disease
Figure 2 Functioning as measured by the Health Assessment
Questionnaire (HAQ) during 3-years follow-up in the initial and delayed
infliximab (IFX) groups, corrected for propensity score. To obtain
corrected HAQ values, means adjusted for propensity quintile were
estimated by repeated measures models. The grey rectangle represents
the period (median 13 months, interquartile range (IQR) 12 to
17 months) during which patients in the delayed group started
methotrexate (MTX)+IFX.
Table 1 Demographic and disease characteristics at the time of inclusion in the BeSt study of patients
treated with initial IFX and delayed IFX
Initial IFX (n = 117) Delayed IFX (n = 67) p Value
Female sex (%) 68 81 0.057
Age at diagnosis, mean (SD) 53.8 (14.1) 49.8 (12.4) 0.054
RF positive (%) 64 75 0.141
Symptom duration (weeks), median (IQR) 23 (13 to 45) 29 (17 to 56) 0.175
Disease duration (weeks), median (IQR) 3 (1 to 5) 2 (1 to 5) 0.069
Tender joints (no.), mean (SD) 13 (6) 16 (7) ,0.001
Swollen joints (no.), mean (SD) 14 (7) 16 (6) 0.049
ESR, median (IQR) 35 (19 to 56) 40 (22 to 68) 0.157
DAS, mean (SD) 4.29 (0.8) 4.73 (0.8) 0.001
HAQ, mean (SD) 1.36 (0.7) 1.49 (0.5) 0.159
Erosion score, median (IQR) 2.0 (0.5 to 5.0) 1.5 (0.5 to 3.5) 0.294
Narrowing score, median (IQR) 1.5 (0.0 to 3.8) 1.5 (0.0 to 4.0) 0.953
Total Sharp score, median (IQR) 4.0 (1.5 to 9.0) 3.0 (1.0 to 7.5) 0.568
Best, Behandel Stratagieen (treatment strategies); DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health
assessment questionnaire; IFX, infliximab; IQR, interquartile range; RF, rheumatoid factor.
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severity at baseline (fig 2). At 3 years, patients in the initial
group had improved with a mean of 0.87 HAQ units vs 0.66
HAQ units in the delayed group (p,0.05), a difference
comparable with the minimal clinically important difference
of 0.22.29 The area under the curve (AUC) for the HAQ of the
initial group was significantly smaller compared with the AUC
of the delayed group (p,0.001, fig 2). Within the delayed group,
we observed no differences in improvement in HAQ between
patients randomised to group 1, 2 or 3.
Joint damage
Radiographs of the hands and feet at baseline and 3-year follow-
up were available in 109 patients from the initial group and 66
patients from the delayed group. Median (IQR) 3-year SHS
progression was 1.5 (0.0 to 4.8) in the initial group vs 4.5 (0.9 to
15.4) in the delayed group (p,0.001). The percentage of
patients with SHS progression .SDC after 3 years was 26%
in the initial group vs 50% in the delayed group (p = 0.001).
After adjustment for propensity score, significant progression of
joint damage (SHS.SDC) was two times less likely in patients
in the initial group compared with patients in the delayed group
(odds ratio (OR) 0.47, 95% CI 0.24 to 0.95, p = 0.034, table 3).
Within the delayed group, group 3 showed a trend for fewer
patients with significant joint damage progression compared
with groups 1 and 2 (33% vs 56% and 56%, overall p = 0.25).
IFX dose and treatment discontinuation
After adjustment for propensity score, patients treated with
initial MTX+IFX were significantly more likely to have
discontinued IFX due to a sustained DAS (2.4 (OR 2.6, 95%
CI 1.3 to 5.2, p = 0.008, table 3). In 28 of 66 patients (42%) in
the initial group and in 9 of 19 patients (47%) in the delayed
group, successful IFX discontinuation was achieved only after
an IFX dose increase. The percentages of patients failing on
MTX+IFX, as well as the reasons for failure in the two groups
were comparable (table 4). Over the 3 years, patients treated
with initial MTX+IFX received on average 9 IFX infusions
corresponding to a median cumulative IFX dose of 40 mg/kg;
patients treated with delayed MTX+IFX received on average 11
IFX infusions corresponding to a median cumulative IFX dose of
48 mg/kg.
Toxicity
Serious adverse events (SAEs) were reported in 19 patients
(16%) in the initial group and 17 patients (25%) in the delayed
group. A possible or probable relation to treatment with
MTX+IFX was reported in seven patients (6%) in the initial
group (instable angina pectoris (two SAEs in one patient),
pneumonia (one), MTX pneumonitis (one), septic arthritis
(one), basal cell carcinoma (one), infusion reaction (one) and
disseminated tuberculosis, eventually resulting in the patients’
death after infectious complications)30 and in seven patients
(10%) in the delayed group (p = 0.27) (pneumonia (two), basal
cell carcinoma (one), facial hyperaemia during infliximab
infusion (one), ulcerative stomatitis (one), osteomyelitis (one)
and disseminated tuberculosis (one), of which the patient
recovered after intensive tuberculostatic treatment).22
DISCUSSION
This post hoc analysis suggests that in patients with recent
onset RA, a strategy of initial MTX+IFX results in significantly
more improvement in functional ability and less radiographic
damage progression over 3 years time than reserving MTX+IFX
for patients who failed on at least three traditional DMARDs. In
addition, more patients initially treated with IFX successfully
tapered and discontinued IFX due to a sustained DAS of (2.4.
The patients who later started IFX had a median delay of only
13 months and median disease duration of 14 months. At this
stage, the HAQ is thought to be mostly related to disease
activity and not structural damage and therefore still sensitive
Table 2 Distribution of characteristics at study inclusion within propensity quintiles
Quintile
1 2 3 4 5
Initial IFX (n = 117) 28 29 13 22 25
Delayed IFX (n = 67) 2 6 9 18 32
Propensity score, median 0.03 0.08 0.14 0.23 0.44
Female sex (%) 47 54 73 80 91
Age at diagnosis, mean 60.3 55.4 55.0 52.3 45.3
RF positive (%) 50 63 82 63 79
Symptom duration (weeks), median 28 27 24 22 24
Tender joints (no.), mean 10 11 14 15 17
Swollen joints (no.), mean 10 13 14 17 17
ESR, median 23 31 31 41 45
DAS, mean 3.69 4.11 4.36 4.76 4.88
HAQ, median 1.25 1.25 1.44 1.50 1.38
DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; IFX, infliximab; RF,
rheumatoid factor.
Table 3 Radiographic progression greater than the smallest detectable change (SDC) after 3 years and IFX
discontinuation 2 years after the start of MTX+IFX in the initial and delayed MTX+IFX groups, adjusted for
propensity score
Initial IFX Delayed IFX Odds ratio (95% CI) p Value
Patients with progression SHS.SDC, % 26 50 0.47 (0.24 to 0.95) 0.034
Patients who discontinued IFX due to a sustained
DAS (2.4, %
56 29 2.56 (1.27 to 5.16) 0.008
DAS, disease activity score; IFX, infliximab; SDC, smallest detectable change; SHS, modified Sharp/van der Heijde Score.
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to change.31 32 Our results suggest that even a relatively short
delay will reduce the possibility of improvement, which supports
the ‘‘window of opportunity’’ hypothesis. A previous study on
immediate vs delayed IFX institution suggested the same.20
An important limitation of this post hoc analysis of a
randomised trial is the fact that the delayed group represents a
selection of patients with possibly more severe RA, which
hampers the interpretation of the results. In daily practice
patient selection is also an issue, since in The Netherlands, as in
most other countries, IFX is available only for patients who
failed on at least two traditional DMARDs including MTX. In
this analysis we used propensity scores, which reduce selection
bias and help to interpret results adjusted for disease severity.23
Using propensity adjustment, the differences between groups at
baseline were no longer significant, and the adjusted outcomes
still suggested that initial IFX provides more benefit than
delayed IFX. However, propensity scoring cannot eliminate any
bias as a result of the treatment dynamics in the different
groups during follow-up, as would also occur in daily practice.
To try to address this point, we compared the results on
functional ability and radiographic progression in the delayed
group separately for groups 1, 2 and 3, and observed no
significant differences between the three groups, although there
was a trend for fewer patients with joint damage progression
during 3 years in group 3, compared with groups 1 and 2.
There appeared to be a twofold decreased risk of significant
joint damage progression in the initial MTX+IFX group.
Unfortunately, only the baseline and 3-year radiographs were
available for scoring. As a consequence, it is uncertain if there
was a relation in time between use or discontinuation of IFX
and radiographic progression. Therefore, the differences in
radiographic progression should be interpreted with caution.
Finally, in the 3-year follow-up from baseline, patients in the
delayed group had less time to receive IFX compared with the
initial group. However, follow-up from the moment IFX was
started in the delayed group was on average 2 years, which
should be sufficiently long to observe a treatment effect and
allow patients to taper and stop IFX. Since more patients in the
initial group tapered and discontinued IFX due to a good
response, the cumulative 3-year IFX doses in both groups were
comparable, despite earlier introduction of IFX in the initial
group. Given the observation that patients treated with delayed
MTX+IFX less often can taper and discontinue IFX, which
corresponds with daily practice,33 differences in the timing of
IFX may also have financial consequences for the future.
The study protocol dictated dose escalation of IFX if the DAS
remained .2.4. Although in the Anti-TNF Trial in Rheumatoid
Arthritis with Concomitant Therapy (ATTRACT) study no
significant differences in outcomes between IFX 3 mg/kg and
10 mg/kg were observed,11 it has been suggested that a subset of
patients benefits from higher IFX doses.34 35 The benefit of dose
escalation is confirmed in our study, because 44% of the patients
who successfully discontinued IFX first needed dose increases .
3 mg/kg to achieve a clinical response. This study was not
designed for, nor capable of comparing toxicity between both
strategies. Treatment related toxicity between both groups
seemed comparable. Two patients (one in either group) developed
disseminated tuberculosis. The patient in the delayed group
recovered after tuberculostatic therapy, but the patient in the
initial group died after a complicated disease course.30
It is evident that prescription of initial MTX+IFX to all patients
with recently diagnosed RA will result in overtreatment of about
a third of the patients, who would have done well on MTX
alone.15 16 It can be expected that such patients will be able to
discontinue IFX quite early, keeping the period of overtreatment
to a minimum. Based on this analysis, we would now suggest that
initial undertreatment could be worse than temporary over-
treatment. Ideally, in the future we should be able to reliably
identify patients with RA who will (1) experience a severe disease
course and thus need TNF antagonists at the time of diagnosis, (2)
experience a mild disease course and hence not need TNF
antagonists, or (3) fail to respond to TNF antagonists and require
alternative (biological) therapies.
In summary, this post hoc analysis suggests that initial
MTX+IFX treatment in patients with recent onset RA is more
effective than reserving this combination for patients who
previously failed on traditional DMARDs, resulting in more
functional improvement, less progression of joint damage and
more patients able to discontinue IFX with maintenance of
good response. These advantages should first be confirmed in
other studies, and could have an additional benefit in terms of
long-term cost effectiveness of IFX treatment.
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